Cargando…
Intranasal Administration of PACAP Is an Efficient Delivery Route to Reduce Infarct Volume and Promote Functional Recovery After Transient and Permanent Middle Cerebral Artery Occlusion
Intranasal (IN) administration appears to be a suitable route for clinical use as it allows direct delivery of bioactive molecules to the central nervous system, reducing systemic exposure and sides effects. Nevertheless, only some molecules can be transported to the brain from the nasal cavity. Thi...
Autores principales: | Cherait, Asma, Maucotel, Julie, Lefranc, Benjamin, Leprince, Jérôme, Vaudry, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855853/ https://www.ncbi.nlm.nih.gov/pubmed/33551991 http://dx.doi.org/10.3389/fendo.2020.585082 |
Ejemplares similares
-
The Potential of the Nose-to-Brain Delivery of PACAP for the Treatment of Neuronal Disease
por: Cherait, Asma, et al.
Publicado: (2023) -
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Protects Striatal Cells and Improves Motor Function in Huntington’s Disease Models: Role of PAC1 Receptor
por: Solés-Tarrés, Irene, et al.
Publicado: (2022) -
Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
por: Hori, Motohide, et al.
Publicado: (2012) -
Correction: Transcriptomics and proteomics analyses of the PACAP38 influenced ischemic brain in permanent middle cerebral artery occlusion model mice
por: Hori, Motohide, et al.
Publicado: (2013) -
Unraveling the Specific Ischemic Core and Penumbra Transcriptome in the Permanent Middle Cerebral Artery Occlusion Mouse Model Brain Treated with the Neuropeptide PACAP38
por: Hori, Motohide, et al.
Publicado: (2015)